Company intelligence / Profile preview
Shanghai Salvectors Biotechnology LTD.
Shanghai, Shanghai Shi, Chinasalvectors.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Salvectors Biotechnology is developing an oncolytic bacterial therapy using genetically modified Salmonella expressing Diphtheria toxin A for the treatment of neuroblastoma. Their lead asset has received FDA Orphan Drug Designation for this indication but remains in preclinical development with no reported clinical results yet.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic bacteria
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Salvectors Biotechnology LTD..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Salvectors Biotechnology LTD..